Meme Kanserinde Adjuvan Radyoterapi

Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249.

Xu H, Xu B. Breast cancer: Epidemiology, risk factors and screening. Chin J Cancer Res. 2023 Dec 30;35(6):565–583.

Huang J, Chan PS, Lok V, et al Global incidence and mortality of breast cancer: a trend analysis. Aging (Albany NY) 2021;13:5748–803.

Trayes KP, Cokenakes SEH. Breast Cancer Treatment. Am Fam Physician. 2021 Aug 1;104(2):171-178.

Maughan KL, Lutterbie MA, Ham PS. Treatment of breast cancer. Am Fam Physician. 2010 Jun 1;81(11):1339-46.

Valente SA, Shah C. The Landmark Series: Adjuvant Radiation Therapy for Breast Cancer. Ann Surg Oncol. 2020 Jul;27(7):2203-2211.

Fisher B, Anderson S. Conservative surgery for the management of invasive and noninvasive carcinoma of the breast: NSABP trials. National Surgical Adjuvant Breast and Bowel Project. World J Surg. 1994;18:63–9.

van Dongen JA, Bartelink H, Fentiman IS, et al. Randomized clinical trial to assess the value of breast-conserving therapy in stage I and II breast cancer, EORTC 10801 trial. J Natl Cancer Inst Monogr. 1992:15–8.

Ragaz J, Olivotto IA, Spinelli JJ, et al. Locoregional radiation therapy in patients with high risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst. 2005;97:116–26.

Overgaard M, Hansen PS, Overgaard J, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med. 1997;337:949–55.

Overgaard M, Jensen MB, Overgaard J, et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet. 1999;353:1641–8.

McGale P, Taylor C, Correa C, et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: metaanalysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 2014;383:2127–35.

Cao L, Ou D, Shen KW, et al. Outcome of postmastectomy radiotherapy after primary systemic treatment in patients with clinical T1-2N1 breast cancer. Cancer Radiother. 2018 Feb;22(1):38-44.

He ZY, Wu SG, Zhou J, et al. Postmastectomy radiotherapy improves disease-free survival of high risk of locoregional recurrence breast cancer patients with T1-2 and 1 to 3 positive nodes. PLoS One. 2015 Mar 17;10(3):e0119105.

NCCN Breast Cancer Panel Members. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Breast Cancer Version 1.2025.

Hughes KS, Schnaper LA, Bellon JR, et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol. 2013 Jul 1;31(19):2382-7.

Fisher B, Bryant J, Dignam JJ, et al. Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. J Clin Oncol. 2002 Oct 15;20(20):4141-9.

Kunkler IH, Williams LJ, Jack WJL, et al. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. Lancet Oncol. 2015 Mar;16(3):266-73.

Early Breast Cancer Trialists’ Collaborative G, Darby S, McGale P, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378:1707–16.

Bentzen SM, Agrawal RK, Aird EG. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol. 2008;9:331–341.

Bentzen SM, Agrawal RK, Aird EG. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet. 2008;371:1098–1107.

Whelan TJ, Pignol JP, Levine MN, et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med. 2010;362:513–20.

Brunt AM, Haviland JS, Wheatley DA, et al. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. Lancet. 2020 May 23;395(10237):1613-1626.

Smith BD, Bellon JR, Blitzblau R. Radiation therapy for the whole breast: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline. Pract Radiat Oncol. 2018;8:145–152.

Ko DH, Norriss A, Harrington CR, et al. Hypofractionated radiation treatment following mastectomy in early breast cancer: The Christchurch experience. J Med Imaging Radiat Oncol. 2015;59:243–247.

Bochenek-Cibor J, Georgiew F, Goyal S. A retrospective analysis on safety and effectiveness of hypofractioned post-mastectomy radiotherapy. Breast J. 2020;26:176–181.

.Eldeeb H, Awad I, Elhanafy O. Hypofractionation in post-mastectomy breast cancer patients: seven-year follow-up. Med Oncol. 2012;29:2570–2576.

Tovanabutra C, Katanyoo K, Uber P, et al. Comparison of treatment outcome between hypofractionated radiotherapy and conventional radiotherapy in postmastectomy breast cancer. Asian Pac J Cancer Prev. 2020;21:119–125.